Please note: The information displayed on this page might be outdated.
Avacta: Avacta (AVCT:LN) develops next-generation biologics using its proprietary Affimer® platform technology. This technology is based on a naturally occurring human protein, engineered to behave like an antibody, but smaller, simpler, more robust, easy to format, cheaper and quicker to produce, highly specific to the target and non-immunogenic. In February 2019, Moderna exercised option on taking Affimer candidate(s) into clinical development.

-Lead assets are PD-L1/LAG-3 single molecule bispecific inhibitor and a PD-L1 tumour microenvironment targeted innate immune activators (I-DASH inhibitors, STING agonists)
-First-in-man clinical data expected in 2020.
-Partnerships with Moderna and OncoSec (Gene delivery), Memorial Sloan Kettering (CAR-T), Iksuda and Tufts University Medical School (Drug conjugates)
-Affimer reagents business for diagnostics and research

Near term newsflow:
-Candidate selection for anti-PD-L1/LAG-3 bispecific Affimer clinical proprietary development – (June 2019)
-Remains on track to submit an IND/CTA application by the end of 2020
-Completion of IND enabling studies for anti-PD-L1/LAG-3 bispecific - 2020
-Affimer therapeutics and reagents/diagnostics licensing
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Pre-Clinical Stage
Disease Space
Immuno-Oncology
Listing
Europe, Public
Market Cap
<100MM
Therapeutic Modalities
Platform Technology
Website:
Profiles:
Address:
Unit 20, Ash Way
Thorp Arch Estate
Wetherby, York LS23 7FA
United Kingdom

Company Participants at European Biotech Investor Day 2019

  • Dr. Alastair Smith, Co-Founder and CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Avacta Group plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Miton Asset Management Ltd. 14.55 16,900,813 28.49 Stakes 2020-05-06
Baillie Gifford & Co. 10.10 11,734,089 19.78 Stakes 2020-06-10
Lombard Odier Asset Management (Europe) Ltd. 8.59 9,979,863 16.82 Stakes 2020-05-06
J.O. Hambro Capital Management Ltd. 7.43 8,625,000 14.54 Stakes 2020-04-21
Hargreaves Lansdown Stockbrokers Ltd. 7.08 8,226,000 13.87 Stakes 2020-04-02
Jarvis Investment Management Ltd. 5.85 6,791,000 11.45 Stakes 2020-04-02
FIL Investment Advisors (UK) Ltd. 5.81 6,754,122 11.38 Stakes 2020-01-02
Unicorn Asset Management Ltd. 5.17 6,000,000 10.11 Stakes 2020-04-24
Ruffer LLP 4.67 5,426,087 9.15 Stakes 2020-04-02
Hargreaves Lansdown Asset Management Ltd. 4.44 5,154,000 8.69 Stakes 2020-04-02
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.